|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/498 | |
| A61K 31/519 | |||
| A61K 45/06 | |||
| A61P 35/00 |
| (11) | Number of the document | 2056829 |
| (13) | Kind of document | T |
| (96) | European patent application number | 07811344.6 |
| Date of filing the European patent application | 2007-08-16 | |
| (97) | Date of publication of the European application | 2009-05-13 |
| (45) | Date of publication and mention of the grant of the patent | 2012-01-04 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2007/018057 |
| Date | 2007-08-16 |
| (87) | Number | WO 2008/021389 |
| Date | 2008-02-21 |
| (30) | Number | Date | Country code |
| 838307 P | 2006-08-16 | US |
| (72) |
AFTAB, Dana, T., US
LAIRD, A., Douglas, US
LAMB, Peter, US
MARTINI, Jean-Francois, A., US
|
| (73) |
Exelixis, Inc.,
210 East Grand Avenue, South San Francisco, CA 94080,
US
|
| (54) | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER |
| USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER |